EP3340994A1 — Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
Assigned to Alnylam Pharmaceuticals Inc · Expires 2018-07-04 · 8y expired
What this patent protects
The invention relates to methods of inhibiting the expression of a PCSK9 gene in a subject, as well as therapeutic and prophylactic methods for treating subjects having a lipid disorder, such as a hyperlipidemia using RNAi agents, e.g., double- stranded RNAi agents, targeting the…
USPTO Abstract
The invention relates to methods of inhibiting the expression of a PCSK9 gene in a subject, as well as therapeutic and prophylactic methods for treating subjects having a lipid disorder, such as a hyperlipidemia using RNAi agents, e.g., double- stranded RNAi agents, targeting the PCSK9 gene.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.